ENSC | tickerfilter.com

Fundamental analysis

33%

Profitability 35%

Dept financing 28%

Liquidity 0%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-8.82%

1 Month

-10.02%

3 Months

-65.81%

6 Months

-73.95%

1 Year

-89.10%

2 Year

-30.39%

Key data

Stock price

$0.55

P/E Ratio

0.00

DAY RANGE

$0.49 - $0.55

EPS

-$8.58

52 WEEK RANGE

$0.31 - $4.93

52 WEEK CHANGE

-$88.67

MARKET CAP

7.035 M

YIELD

N/A

SHARES OUTSTANDING

3.541 M

DIVIDEND

$0.00

EX-DIVIDEND DATE

12-06-2024

NEXT EARNINGS DATE

05-12-2025

BETA

-0.44

PUBLIC FLOAT

AVERAGE 10 VOLUME

$38,133,928

AVERAGE 30 VOLUME

$16,922,020

Company detail

CEO: D. Lynn Kirkpatrick, PhD
Region: US
Website: ensysce.com
Employees: 10
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Ensysce Biosciences, Inc. engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended. release prodrugs of amphetamine for ADHD medication abuse.

ENSC - Ensysce Biosciences Inc